Royal Bank of Canada
RCEL icon

Royal Bank of Canada’s Avita Medical RCEL Stock Holding History

Royal Bank of Canada’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
97
-5,543
-98% -$23.3K ﹤0.01% 7589
2025
Q4 		$19K Buy
5,640
+1,167
+26% +$4.66K ﹤0.01% 6085
2025
Q3 		$23K Buy
4,473
+4,389
+5,225% +$22.9K ﹤0.01% 6152
2025
Q2 		$0 Sell
84
-787
-90% -$5.72K ﹤0.01% 7287
2025
Q1 		$7K Buy
871
+134
+18% +$1.25K ﹤0.01% 6271
2024
Q4 		$10K Sell
737
-2,041
-73% -$24.1K ﹤0.01% 6350
2024
Q3 		$30K Buy
2,778
+212
+8% +$1.99K ﹤0.01% 5936
2024
Q2 		$20K Buy
2,566
+1,024
+66% +$9.74K ﹤0.01% 6079
2024
Q1 		$25K Sell
1,542
-5,489
-78% -$88.8K ﹤0.01% 5831
2023
Q4 		$97K Buy
7,031
+3,077
+78% +$35.3K ﹤0.01% 5641
2023
Q3 		$58K Buy
3,954
+2,245
+131% +$38K ﹤0.01% 5706
2023
Q2 		$30K Buy
1,709
+620
+57% +$9.1K ﹤0.01% 6015
2023
Q1 		$16K Buy
1,089
+689
+172% +$7.33K ﹤0.01% 6116
2022
Q4 		$3K Hold
400
– – ﹤0.01% 6869
2022
Q3 		$2K Hold
400
– – ﹤0.01% 7055
2022
Q2 		$2K Sell
400
-1,493
-79% -$9.22K ﹤0.01% 6985
2022
Q1 		$16K Sell
1,893
-3,996
-68% -$36.8K ﹤0.01% 6726
2021
Q4 		$70K Buy
5,889
+2,799
+91% +$42.7K ﹤0.01% 6180
2021
Q3 		$55K Buy
3,090
+1,056
+52% +$19.9K ﹤0.01% 6105
2021
Q2 		$42K Buy
2,034
+1,634
+409% +$32.2K ﹤0.01% 6152
2021
Q1 		$8K Hold
400
– – ﹤0.01% 6897
2020
Q4 		$7K Sell
400
-68
-15% -$1.49K ﹤0.01% 6540
2020
Q3 		$12K Buy
468
+28
+6% +$698 ﹤0.01% 5872
2020
Q2 		$13K Sell
440
-198
-31% -$6.05K ﹤0.01% 5745
2020
Q1 		$20K Sell
638
-300
-32% -$12.4K ﹤0.01% 5548
2019
Q4 		$43K Buy
+938
New +$39K ﹤0.01% 5521

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada's RCEL Position: Q1 2026 in Review

Royal Bank of Canada reduced its Avita Medical (RCEL) stake by 98% in Q1 2026, selling an estimated $23.3K and leaving 97 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7589.

Royal Bank of Canada first reported a position in RCEL in Q4 2019 and has held it in 26 quarters since. The position peaked at $97K in Q4 2023. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Royal Bank of Canada held 97 shares of Avita Medical worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 5,543 Avita Medical shares in Q1 2026, an estimated $23.3K.
  • Avita Medical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7589 holding.
  • Royal Bank of Canada first reported a position in Avita Medical in Q4 2019 and has held it in 26 quarters since.
  • Royal Bank of Canada's Avita Medical position peaked at $97K in Q4 2023.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.